Ani Pharmaceuticals Stock Probability Of Bankruptcy

ANIP Stock

USD 60.19 0.38 0.64%

ANI Pharmaceuticals' odds of distress is under 10% at this time. It has tiny probability of undergoing some form of financial hardship in the near future. Probability of distress prediction helps decision makers evaluate ANI Pharmaceuticals' chance of financial distress in relation to its going-concern outlook and evaluation. All items used in analyzing the odds of distress are taken from the ANI balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out ANI Pharmaceuticals Piotroski F Score and ANI Pharmaceuticals Altman Z Score analysis.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

As of 02/07/2025, Market Cap is likely to grow to about 496.8 M, while Enterprise Value is likely to drop slightly above 43 M.

ANI Pharmaceuticals Company probability of distress Analysis

ANI Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current ANI Pharmaceuticals Probability Of Bankruptcy

Less than 10%

Most of ANI Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of ANI Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting ANI Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of ANI Pharmaceuticals financial health.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

13.824

Earnings Share

(0.47)

Revenue Per Share

28.915

Quarterly Revenue Growth

0.125

Return On Assets

0.0125

The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ANI Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		0.99	0.5	0.12	0.96	0.99	0.96	-0.46	-0.25	0.67	0.98	0.17	0.97	0.93	0.67	0.65	-0.8	0.78	0.91	0.88	-0.8	0.84	0.86	0.9	-0.77
Total Stockholder Equity	0.99		0.41	0.09	0.96	0.98	0.98	-0.44	-0.22	0.7	0.96	0.22	0.96	0.93	0.65	0.69	-0.75	0.73	0.87	0.86	-0.76	0.85	0.89	0.91	-0.78
Net Debt	0.5	0.41		0.34	0.36	0.57	0.24	-0.43	-0.21	0.06	0.55	-0.49	0.51	0.38	0.55	-0.03	-0.75	0.88	0.71	0.57	-0.66	0.3	0.13	0.33	-0.25
Retained Earnings	0.12	0.09	0.34		-0.07	0.14	0.01	-0.88	0.4	0.07	0.05	-0.18	0.14	-0.11	0.19	-0.08	-0.22	0.37	0.23	0.07	-0.09	-0.14	-0.18	-0.16	0.2
Accounts Payable	0.96	0.96	0.36	-0.07		0.94	0.96	-0.31	-0.41	0.63	0.97	0.27	0.92	0.96	0.59	0.7	-0.76	0.62	0.84	0.84	-0.77	0.89	0.94	0.94	-0.86
Total Liab	0.99	0.98	0.57	0.14	0.94		0.93	-0.47	-0.27	0.64	0.98	0.11	0.97	0.91	0.68	0.6	-0.84	0.83	0.93	0.89	-0.84	0.82	0.82	0.88	-0.76
Total Current Assets	0.96	0.98	0.24	0.01	0.96	0.93		-0.37	-0.24	0.75	0.93	0.37	0.93	0.92	0.58	0.73	-0.66	0.59	0.78	0.82	-0.7	0.86	0.93	0.91	-0.82
Common Stock	-0.46	-0.44	-0.43	-0.88	-0.31	-0.47	-0.37		-0.19	-0.38	-0.42	-0.01	-0.48	-0.31	-0.43	-0.15	0.43	-0.55	-0.48	-0.42	0.36	-0.25	-0.22	-0.26	0.22
Short Term Debt	-0.25	-0.22	-0.21	0.4	-0.41	-0.27	-0.24	-0.19		0.08	-0.37	0.09	-0.27	-0.41	-0.23	-0.23	0.35	-0.11	-0.3	-0.27	0.62	-0.4	-0.47	-0.43	0.36
Current Deferred Revenue	0.67	0.7	0.06	0.07	0.63	0.64	0.75	-0.38	0.08		0.62	0.31	0.67	0.62	0.39	0.56	-0.18	0.37	0.34	0.56	-0.39	0.57	0.69	0.61	-0.74
Net Receivables	0.98	0.96	0.55	0.05	0.97	0.98	0.93	-0.42	-0.37	0.62		0.13	0.96	0.94	0.66	0.63	-0.83	0.77	0.91	0.88	-0.83	0.85	0.87	0.92	-0.83
Net Tangible Assets	0.17	0.22	-0.49	-0.18	0.27	0.11	0.37	-0.01	0.09	0.31	0.13		0.24	0.32	0.07	0.2	0.07	-0.28	-0.02	0.21	0.07	0.31	0.37	0.34	-0.35
Long Term Debt	0.97	0.96	0.51	0.14	0.92	0.97	0.93	-0.48	-0.27	0.67	0.96	0.24		0.92	0.73	0.58	-0.77	0.78	0.88	0.89	-0.84	0.82	0.85	0.89	-0.75
Good Will	0.93	0.93	0.38	-0.11	0.96	0.91	0.92	-0.31	-0.41	0.62	0.94	0.32	0.92		0.57	0.63	-0.69	0.63	0.8	0.88	-0.73	0.91	0.92	1.0	-0.84
Long Term Debt Total	0.67	0.65	0.55	0.19	0.59	0.68	0.58	-0.43	-0.23	0.39	0.66	0.07	0.73	0.57		0.3	-0.66	0.71	0.69	0.76	-0.74	0.61	0.51	0.53	-0.44
Long Term Investments	0.65	0.69	-0.03	-0.08	0.7	0.6	0.73	-0.15	-0.23	0.56	0.63	0.2	0.58	0.63	0.3		-0.31	0.26	0.46	0.47	-0.39	0.64	0.75	0.62	-0.49
Treasury Stock	-0.8	-0.75	-0.75	-0.22	-0.76	-0.84	-0.66	0.43	0.35	-0.18	-0.83	0.07	-0.77	-0.69	-0.66	-0.31		-0.82	-0.97	-0.76	0.81	-0.62	-0.52	-0.64	0.54
Intangible Assets	0.78	0.73	0.88	0.37	0.62	0.83	0.59	-0.55	-0.11	0.37	0.77	-0.28	0.78	0.63	0.71	0.26	-0.82		0.86	0.81	-0.76	0.59	0.43	0.59	-0.42
Property Plant Equipment	0.91	0.87	0.71	0.23	0.84	0.93	0.78	-0.48	-0.3	0.34	0.91	-0.02	0.88	0.8	0.69	0.46	-0.97	0.86		0.82	-0.83	0.7	0.65	0.75	-0.58
Capital Surpluse	0.88	0.86	0.57	0.07	0.84	0.89	0.82	-0.42	-0.27	0.56	0.88	0.21	0.89	0.88	0.76	0.47	-0.76	0.81	0.82		-0.75	0.92	0.75	0.86	-0.73
Short Long Term Debt	-0.8	-0.76	-0.66	-0.09	-0.77	-0.84	-0.7	0.36	0.62	-0.39	-0.83	0.07	-0.84	-0.73	-0.74	-0.39	0.81	-0.76	-0.83	-0.75		-0.67	-0.69	-0.71	0.6
Net Invested Capital	0.84	0.85	0.3	-0.14	0.89	0.82	0.86	-0.25	-0.4	0.57	0.85	0.31	0.82	0.91	0.61	0.64	-0.62	0.59	0.7	0.92	-0.67		0.88	0.92	-0.78
Net Working Capital	0.86	0.89	0.13	-0.18	0.94	0.82	0.93	-0.22	-0.47	0.69	0.87	0.37	0.85	0.92	0.51	0.75	-0.52	0.43	0.65	0.75	-0.69	0.88		0.93	-0.84
Capital Stock	0.9	0.91	0.33	-0.16	0.94	0.88	0.91	-0.26	-0.43	0.61	0.92	0.34	0.89	1.0	0.53	0.62	-0.64	0.59	0.75	0.86	-0.71	0.92	0.93		-0.84
Accumulated Depreciation	-0.77	-0.78	-0.25	0.2	-0.86	-0.76	-0.82	0.22	0.36	-0.74	-0.83	-0.35	-0.75	-0.84	-0.44	-0.49	0.54	-0.42	-0.58	-0.73	0.6	-0.78	-0.84	-0.84

Click cells to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition

Predict ANI Pharmaceuticals

Based on the latest financial disclosure, ANI Pharmaceuticals has a Probability Of Bankruptcy of 10.0%. This is 76.9% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 74.89% higher than that of the company.

ANI Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.

ANI Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.

ANI Pharmaceuticals Main Bankruptcy Drivers

	2020	2021	2022	2023	2024	2025 (projected)
Return On Assets	(0.0489)	(0.0552)	(0.063)	0.0208	0.0187	0.0196
Gross Profit Margin	0.69	0.58	0.53	0.56	0.63	0.34
Net Debt	177.8M	187.1M	238.3M	64.5M	74.2M	38.9M
Total Current Liabilities	78.6M	87.5M	99.4M	145.5M	167.3M	175.7M
Non Current Liabilities Total	186.9M	325.3M	322.1M	301.3M	346.5M	363.9M
Total Assets	461.2M	771.6M	760.1M	904.4M	1.0B	1.1B
Total Current Assets	170.3M	321.8M	344.3M	519.8M	597.8M	627.7M
Total Cash From Operating Activities	15.3M	3.3M	(31.2M)	119.0M	136.8M	143.6M

ANI Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

ANI Fundamentals

	Return On Equity	-0.016
	Return On Asset	0.0125
	Profit Margin	(0.01) %
	Operating Margin	(0.07) %
	Current Valuation	1.75 B
	Shares Outstanding	21.02 M
	Shares Owned By Insiders	10.54 %
	Shares Owned By Institutions	89.46 %
	Number Of Shares Shorted	2.29 M
	Price To Earning	43.35 X
	Price To Book	3.10 X
	Price To Sales	2.28 X
	Revenue	486.82 M
	Gross Profit	332.11 M
	EBITDA	106.6 M
	Net Income	18.78 M
	Cash And Equivalents	63.38 M
	Cash Per Share	3.89 X
	Total Debt	285.67 M
	Debt To Equity	0.85 %
	Current Ratio	3.35 X
	Book Value Per Share	20.74 X
	Cash Flow From Operations	118.96 M
	Short Ratio	8.77 X
	Earnings Per Share	(0.47) X
	Price To Earnings To Growth	1.06 X
	Target Price	78.67
	Number Of Employees	642
	Beta	0.71
	Market Capitalization	1.27 B
	Total Asset	904.42 M
	Retained Earnings	(80.13 M)
	Working Capital	374.34 M
	Current Asset	192.58 M
	Current Liabilities	11.76 M
	Net Asset	904.42 M

About ANI Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ani Pharmaceuticals Stock Probability Of Bankruptcy

ANI Pharmaceuticals Company probability of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current ANI Pharmaceuticals Probability Of Bankruptcy

ANI Probability Of Bankruptcy Driver Correlations

ANI Probability Of Bankruptcy Peer Comparison

ANI Pharmaceuticals Main Bankruptcy Drivers

ANI Pharmaceuticals ESG Sustainability

ANI Fundamentals

About ANI Pharmaceuticals Fundamental Analysis

Additional Tools for ANI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY